NeuroPace Inc (NAS:NPCE)
$ 7.53 -0.07 (-0.92%) Market Cap: 216.62 Mil Enterprise Value: 232.78 Mil PE Ratio: 0 PB Ratio: 15.23 GF Score: 55/100

Neuropace Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2024 / 03:30PM GMT
Release Date Price: $11.86 (-4.35%)
Lily Lozada JPMorgan;Analyst

Great. Hey, everyone. Good morning. I'm Lily Lozada, I'm on the medtech research team here at JPMorgan. And I'm happy to have the NeuroPace management team with us here today.

I'll pass it over to CEO, Joel Becker, for a presentation, and then we'll do some Q&A.

Joel Becker
Neuropace Inc - President, Chief Executive Officer, Director

Good morning. Thank you, Lily. Thank you to JP Morgan as well for having us. And thanks to all of you for being with us here, bright and early on a Thursday morning, and to everybody joining.

My name is Joel Becker. I'm the President and CEO of NeuroPace. And I'm excited to be here with our leadership team, members of our leadership team, to tell you about who we are and what we do, our current status, and why we're excited about where we're headed. So with that, I'll get right to it.

Please note our disclaimers. And I'll start with who NeuroPace is. It's best defined by our mission. You can see it here. And that is to transform the lives of people suffering

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot